4.17.20
10 min. Read

Analysis: FDA’s new guidance for digital therapeutics

Issue 048.

Get E&O weekly. | Subscribe

Digital health research from Brian Dolan.

Welcome to E&O.

Last week's newsletter had a 59 percent open rate. Here's what's happening this week:

  • As part of the effort to make virtual care more accessible during the COVID--19 pandemic, the FDA posted a new enforcement guidance focused on digital health devices for the treatment of psychiatric disorders. Given how many DTx companies are focused on behavioral health, this move by the FDA has a lot of companies re-examining their go-to-market timeline. I pushed back the MSK report a few days as I've been on the phone with readers non-stop trying to getting my head around this guidance. Read more on the FDA's in today's top story below...
  • Decisions Resources Group has a worthwhile report out on payers' perspectives around digital therapeutics that is based on responses from 157 P&T committee members at

Paying Subscribers Only

It's a good one, too.
This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!
×

Full access to E&O's research and newsletters.

Get the subscribers-only newsletters + research reports + databases
Help me get ahead. $200/year

Prescription Digital Therapeutics

All Newsletters
    223 articles
  • First
  • Previous
    • 1 of 23
  • Next
  • Last
New wearable BP 510(k) sheds light on Whoop-FDA. Trials: BetterHelp, Click, DynamiCare, Axena, Kaiser
8.08.25
8 min. Read
CMS RFI review: 12 ideas from health tech cos
7.25.25
10 min. Read
CMS proposes changes to digital mental health G codes, four year test of online DPP reimbursement.
7.16.25
10 min. Read
Digital mental health G code adoption “slow and challenging”
7.11.25
9 min. Read
FDA clears Lumosity-maker’s DTx for ADHD. Withings 510(k) for ECG app.
6.16.25
5 min. Read
PHTI’s premature PDT pricing analysis. CPT billing code rejects.
5.23.25
7 min. Read
PDT bill is back. Anthem covers Luminopia. FDA PCCP for Cognoa.
5.16.25
7 min. Read
More Mahana assets acquired. Luminopia FDA details
5.02.25
7 min. Read
Is it enough? Early MAC pricing for new digital mental health treatment code
4.18.25
6 min. Read
Scoop: Whoop’s first FDA clearance (and what will likely be its second)
4.10.25
7 min. Read
  • First
  • Previous
    • 1 of 23
  • Next
  • Last